The Cigna Group sets new share repurchase plan, health insurer stock in analyst focus
25.06.2026 - 15:10:44 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 15:10.
The Cigna Group (US1255091092) underpins its capital return strategy with a newly authorized $5 billion share repurchase program, as detailed in a recent investor presentation. The New York Stock Exchange-listed health insurer remains a significant S&P 500 constituent and a regular subject of Wall Street research coverage.
Fresh buyback authorization and capital returns
According to Cigna's latest strategic and capital allocation update, the board has put in place an additional $5 billion share repurchase authorization on top of existing capacity, reinforcing an ongoing multi-year focus on buybacks and dividends. In its first-quarter 2025 materials, Cigna highlighted that it had already returned several billion dollars to shareholders through repurchases and dividends over the prior twelve months, while keeping balance sheet metrics within target ranges. The Cigna investor presentation on capital deployment provides the detailed authorization figures.
Management continues to emphasize disciplined capital deployment, stating in the same update that the priority order remains organic investment in the Evernorth health services segment, support for the Cigna Healthcare insurance operations, bolt-on mergers and acquisitions, and then excess capital return via buybacks and a growing dividend. The company noted that common dividends paid in the prior fiscal year totaled well over $1 billion, with the board aiming for a payout ratio that grows in line with earnings per share over time.
Analyst views and S&P 500 role
Analyst consensus compiled by MarketScreener shows that most covering brokers currently rate The Cigna Group shares as Buy or equivalent, with an average twelve-month price target that sits meaningfully above the recent trading range on the NYSE. The consensus expects mid-single-digit to high-single-digit annual revenue growth over the next two to three years, driven primarily by the Evernorth pharmacy benefit management and specialty services businesses. The MarketScreener consensus overview for Cigna summarizes current analyst ratings and targets.
In a recent research comment, JPMorgan reiterated an Overweight stance on large-cap U.S. managed care names including Cigna, citing resilient commercial insurance trends and steady cash generation to support buybacks and dividends. The bank highlighted that Cigna's diversified model, with a substantial contribution from Evernorth's fees and services, offers some protection against policy changes that primarily affect traditional insurance underwriting. A recent Reuters sector piece on U.S. health insurers referenced Cigna alongside peers UnitedHealth and Elevance Health.
All news and analysis on The Cigna Group shares
Track previous coverage, price-sensitive disclosures and background reporting on The Cigna Group with our dedicated topic page and the company's own investor relations portal.
How Cigna makes its money
The Cigna Group primarily generates revenue through two segments, Cigna Healthcare and Evernorth Health Services. The Cigna Healthcare segment earns premiums from commercial, government and international medical insurance products, while Evernorth provides pharmacy benefit management, specialty pharmacy and other health services to corporate and institutional clients.
Where the stock trades today
As of 2026-06-25, 13:00, The Cigna Group shares trade on the New York Stock Exchange at 338.50 USD.
The Cigna Group at a glance
- Company: The Cigna Group Inc.
- ISIN: US1255091092
- WKN: A3EW12
- Ticker: CI
- Trading venue: NYSE
- Price (as of 2026-06-25, 13:00): 338.50 USD
- Market cap: 93.0 billion USD (as of 2026-06-25)
- Sector / industry: Health Care - Managed Health Care and Services
- Index membership: S&P 500
- Next earnings date: 2026-08-01
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
